BDMAI’s e-marketing portal to promote Indian pharma products and services

Mumbai:  With the launch of the Bulk Drug Manufacturers Association of India (BDMAI)’s e-marketing portal, Indian pharma companies can now promote exclusively Indian APIs, intermediates, pellets, impurities, contract development and manufacturing organization (CDMO)/contract research and manufacturing services (CRAM) services in domestic and global markets, according to industry experts.

Designed as a one-stop digital marketplace, this platform aims to strengthen industry visibility, enhance connectivity, and support the global outreach of Indian bulk drug manufacturers.

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has also urged its member companies to register as BUYER, start search and send enquiries for selected products/manufacturers. The portal offers exclusive no cost to the buyers of APIs.

“It also has a Vendor Management facility which can help in creating a comprehensive and integrated ecosystem for the industry as most of our members are into manufacturing of finished formulations, this portal www.bdmaiem.inhelps in souring of APIs,” informs Pharmexcil director general (DG) K. Raja Bhanu.

The portal allows users to search by product name, company name, CAS number, or HS code, making it simple and efficient to find specific products or manufacturers. It also features an integrated enquiry system, allowing users to send direct enquiries to selected companies through the app itself.

BDMAI brings together the leading manufacturers of APIs, intermediates, pallets, impurities, CDMOs and other related service providers from across the country. Established in 1991 with the aim of promoting the growth, competitiveness, and global standing of India’s bulk drug industry, the Association serves as a unified platform for collaboration, representation, and advancement. It works closely with Central and state governments, regulatory authorities, and industry stakeholders to address common challenges and advocate for policies that strengthen the bulk drug manufacturing ecosystem.

Beyond policy advocacy, the Association actively engages in knowledge sharing, technical seminars, training programs, and industry–academia collaborations to support continuous improvement in quality, compliance, innovation, and sustainability.

Related Posts

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India, a leader in advanced diagnostic imaging and healthcare technology, has installed and commissioned the Fujifilm Echelon Smart MRI at Jansons Health in Erode. The installation expands access to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure